Real-World Semaglutide Results: 1.2% HbA1c Drop in Complex Diabetic Patients | Research

The takeaway

In a real-world study of 2,168 medically complex type 2 diabetes patients, once-weekly semaglutide 1.0 mg reduced HbA1c by an average of 1.2% — confirming clinical trial results translate to everyday practice.

-1.2% HbA1c in real world
Semaglutide delivered a meaningful 1.2% HbA1c reduction in medically complex patients averaging 13.5 medication classes — matching clinical trial performance

What the researchers found

Among 2,168 patients with T2D and baseline HbA1c ≥7% who initiated once-weekly semaglutide 1.0 mg, the mean HbA1c reduction was 1.2% (p<0.001). Similar reductions were observed in the persistent patient subgroup (those with at least 90 days of continuous treatment).

The patient population was notably medically complex: patients were taking an average of 13.5 different medication classes, and comorbidity rates were high — lipid metabolism disorder (90.8%), hypertension (86.6%), diabetes with complications (86.8%), and other metabolic disorders (72.5%). Despite this burden of disease, semaglutide consistently lowered blood sugar, confirming its effectiveness in the most challenging real-world patient populations.

Why it matters

Clinical trials select for healthier, more adherent patients — often excluding the complex, multi-morbid patients who make up most real-world diabetes care. This study demonstrates that semaglutide's blood sugar-lowering benefits are preserved in patients with extensive comorbidities and polypharmacy. For clinicians hesitating to prescribe semaglutide to their most complex patients, this data provides real-world reassurance.

How the study worked

Retrospective observational study using the Optum Research Database (US insurance claims). Adult patients with T2D and HbA1c ≥7% who initiated once-weekly semaglutide between January 2018 and December 2019 and were prescribed the 1.0 mg maintenance dose were included. Patients needed continuous health plan enrollment for 12 months before and after initiation. HbA1c change was calculated as the difference between the latest post-index and pre-index measurement. A subgroup analysis of persistent patients (≥90 days continuous treatment) was also performed.

What this study cannot tell us

This is a retrospective study using insurance claims data, which may have coding inaccuracies and cannot capture all clinical variables (diet, exercise, adherence patterns). There was no control group, so the HbA1c reduction cannot be definitively attributed to semaglutide versus concurrent medication changes or lifestyle factors. Only patients on the 1.0 mg maintenance dose were included, excluding those on lower doses or who didn't reach maintenance. The 2018-2019 timeframe represents early semaglutide adoption and may not reflect current prescribing patterns.

How to read the evidence

This is a retrospective real-world observational study using insurance claims data. While it confirms clinical trial findings translate to practice, the absence of a control group and reliance on administrative data limit the strength of causal inference. The large sample (2,168) and comprehensive comorbidity characterization are strengths.

When this study was published

Published in 2024 using 2018-2019 data, this study reflects the early real-world experience with once-weekly semaglutide for diabetes. The drug has since become much more widely prescribed, and newer formulations (higher doses, oral versions) have expanded the treatment options.

The bigger picture

Real-world evidence studies like this are essential for bridging the gap between clinical trial efficacy and everyday clinical effectiveness. The 1.2% HbA1c reduction is consistent with the SUSTAIN clinical trial program results, validating that semaglutide performs as expected outside of controlled research settings. As insurance coverage decisions increasingly rely on real-world evidence, studies like this strengthen the case for semaglutide reimbursement across diverse patient populations.

Questions still open

How does semaglutide's real-world HbA1c reduction compare across different subgroups — higher vs lower baseline HbA1c, more vs fewer comorbidities?
What proportion of patients who started semaglutide achieved the 1.0 mg maintenance dose, and did those who stayed at lower doses still benefit?
Would higher-dose semaglutide (2.0 mg, now available) produce even greater real-world HbA1c reductions?

Common questions

Do clinical trial results for semaglutide hold up in everyday patients?

Yes — this study shows they do. The 1.2% HbA1c reduction is consistent with what the SUSTAIN clinical trials found, even though real-world patients were far more complex: averaging 13.5 different medication types and high rates of complications, high blood pressure, and cholesterol disorders. This is reassuring evidence that semaglutide works as expected outside of controlled research environments.

Why were patients taking so many medications?

The average of 13.5 medication classes reflects the reality of type 2 diabetes — it rarely exists alone. Most patients also have high blood pressure (86.6%), high cholesterol (90.8%), and diabetes complications (86.8%). Each condition requires its own medications, leading to complex drug regimens. The fact that semaglutide still worked well despite this polypharmacy is important for clinicians managing these multi-morbid patients.

Read the original research

Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes.

Journal of health economics and outcomes research, 11(2), 118-124

View on PubMed ↗Publisher’s paper ↗

Citation

Gronroos, Noelle N; Swift, Caroline; Frazer, Monica S; Sargent, Andrew; Leszko, Michael; Buysman, Erin; Alvarez, Sara; Dunn, Tyler J; Noone, Josh. (2024). Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes.. Journal of health economics and outcomes research, 11(2), 118-124. https://doi.org/10.36469/001c.124111